This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Diz-Kucukkaya, R Articles by Pekcelen, Y Search for Related Content PubMed PubMed Citation Articles by Diz-Kucukkaya, R Articles by Pekcelen, Y Social Bookmarking                         What's this?

Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome

Division of Hematology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, rkucukkaya{at}hotmail.com

V S Hancer

Division of Hematology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

M Inanc

Department of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

M Nalcaci

Division of Hematology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Y Pekcelen

Division of Hematology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

The effect of thrombophilic mutations in the development of thrombosis in patients with antiphospholipid syndrome (APS) has been extensively investigated. Factor XIII (FXIII) Val34Leu polymorphism is a newly described polymorphism which is located in the three amino acids away from the thrombin activation site of the FXIII-A subunit. It has been reported that the Leu allele decreases the risk of both arterial and venous thrombosis. In the present study, we examined the associationbetween the FXIII Val34Leu polymorphismand the developmentof thrombosisin patients with APS. Sixty APS patients with arterial and venous thrombosis, 22 antiphospholipid antibody (aPLA) positive patients with first trimester abortus and/or thrombocytopenia,126 healthy controls, and 60 healthy subjects who were age- and sex-matched with thrombotic APS group were included into the study. FXIII Leu allele frequencies in the APS patients with thrombosis, aPLA-positive patients without thrombosis, healthy controls, and matched controls were 13.3, 16, 19.5, and 18.3%, respectively. When we compared Leu allele frequencies between APS patients with thrombosis and aPLA-positive patients without thrombosis, healthy controls or matched controls, we could not find any difference (x ², P 0.43, and P 0.09, P 0.67, respectively). Our results showed that the FXIII Leu allele has no protectiveeffect in the developmentof thrombosis in APS.

Key Words: antiphospholipid syndrome • factor XIII Val34Leu polymorphism • thrombosis

Lupus, Vol. 13, No. 1, 32-35 (2004)
DOI: 10.1191/0961203304lu479oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?